Search Follow us
Sparks Team
27 November 2018 · 3 min read

De La Rue (DLAR); reports good growth in group revenue for H119

Order intake grew by 30% year on year in the first half

De La Rue announced its half year results for the six months ended 29 September 2018. Excluding the paper business, group revenues grew by 9%, driven by growth across all segments. Adjusted operating profit was £17m, mainly reflecting a less favorable mix of orders. IFRS operating profit was £10.1m (down 59% from the previous period).

Read more...
27 November 2018 · 2 min read

Greggs (GRG); unexpectedly upgrades its expectations for the year

Total sales are up 9.0% for the eight weeks to 24 November 2018

Greggs has unexpectedly upgraded expectations to pre-tax profit for the year ended December 2018 of no less than £86m. This represents a 6% upgrade to forecasts of £81.3m.

Read more...
27 November 2018 · 3 min read

Oriole Resources (ORR.L): gold Bonanza nothing to be jumping out of your seat for

Oriole reports “Bonanza Gold Grades at Bibemi” from rock-chip samples

Oriole Resources announced this morning the results of a sampling programme from 454 rock-chip samples, with the heading “Bonanza Gold Grades at Bibemi, Cameroon”, but what do these results really mean?

Read more...
Sparks Team
27 November 2018 · 3 min read

Quiz (QUIZ); EPS increases 5% to 2.46p in H119

EBITDA increased 11% YoY

Group revenue increased 19% YoY to £66.7m in the six months ending 30 September 2018. All channels showed strong growth, led by online revenue (44% growth), international sales (16%) and revenue from UK stores and concessions (9%).

Read more...
Sparks Team
27 November 2018 · 2 min read

Severfield (SFR): interim results reveal revenue up 9% to £149.1m

UK order book stands at £230m

With a UK order book of £230m and India expansion underway, Severfield has continued to make progress during H118 ended 30 September 2018. Severfield’s interims report underlying PBT up 2% to £13.1m against H117 profit of £12.9m. Interim dividends of 1.0p (H117: 0.9p per share) per share have also been announced.

Read more...
Sparks Team
27 November 2018 · 2 min read

Treatt (TET); reports strong growth with headline revenue up 10.8% to £112.2m

Strong results for the year ended 30 September 2018

Treatt’s reported today that revenue grew by 14.1% on a constant currency basis and gross profit was up 9.9% at £27.8m, while operating profit was up 11.1% at £13.9m. Adjusted profit before tax increased by 8.1% to £12.6m, with a 9.8% increase in adjusted basic earnings per share at 18.02p.

Read more...
26 November 2018 · 2 min read

Kodel Minerals (KOD); leaves some fairly important questions unanswered

Kodel Minerals reported assay results from three holes within the Boumou Prospect of its Bougouni Lithium Project

The ongoing publication of assay results without any context for prospective investors or existing shareholders to make their investment decision continues. Kodel Minerals provided a prime example of this in it’s latest RNS published this morning.

Read more...
26 November 2018

Cake Box (CBOX); appears to be doing everything right

Pre-tax profit is up 34% at £1.97m on revenue up 44% at £8.28m

With traditional retail in disarray, and cake not being the most popular word for investors after Patisserie Valerie, it almost seems that Cake Box comes from another, more straightforward age. Following its June IPO, Cake Box has reported maiden interim results to September in which it appears to be doing everything right.

Read more...
Sparks Team
26 November 2018 · 2 min read

Hutchison China MediTech (HCM); launches VEGFR inhibitor fruquintinib

Fruquintinib is the first first pharmaceutical developed for a mainstream oncology indication to be unconditionally developed and approved in China.

Hutchison China Meditech (HMC) announced the first commercial launch of fruquintinib capsules (Elunate) in China.  Fruquintinib is being developed for the treatment of patients with metastatic colorectal cancer (CRC). The market launch of fruquintinib was conducted through collaboration with HCM’s partner Eli Lilly and Company.

Read more...
Sparks Team
26 November 2018 · 2 min read

Palace Capital (PCA); reports IFRS PAT up 67.1% at £7.3m

Maintained income and capital growth

The total accounting return was reported at 4%. EPRA NAV per share increased 1.4% to 421p and dividends were at 4.75p per quarter. The portfolio valuation was up 2.4% at £283.3m compared to £276.7m at 31 March 2018. The gross rental income increased 29% to £9.2m.

Read more...